Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and isavuconazole's effects on CYP3A4‐mediated metabolism in healthy adults. Coadministration of oral isavuconazole (100 mg once daily) with oral...
Saved in:
| Published in | Clinical pharmacology in drug development Vol. 6; no. 1; pp. 44 - 53 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Wiley Subscription Services, Inc
01.01.2017
John Wiley and Sons Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and isavuconazole's effects on CYP3A4‐mediated metabolism in healthy adults. Coadministration of oral isavuconazole (100 mg once daily) with oral rifampin (600 mg once daily; CYP3A4 inducer) decreased isavuconazole area under the concentration‐time curve (AUCτ) during a dosing interval by 90% and maximum concentration (Cmax) by 75%. Conversely, coadministration of isavuconazole (200 mg single dose) with oral ketoconazole (200 mg twice daily; CYP3A4 inhibitor) increased isavuconazole AUC from time 0 to infinity (AUC0‐∞) and Cmax by 422% and 9%, respectively. Isavuconazole was coadministered (200 mg 3 times daily for 2 days, then 200 mg once daily) with single doses of oral midazolam (3 mg; CYP3A4 substrate) or ethinyl estradiol/norethindrone (35 μg/1 mg; CYP3A4 substrate). Following coadministration, AUC0‐∞ increased 103% for midazolam, 8% for ethinyl estradiol, and 16% for norethindrone; Cmax increased by 72%, 14%, and 6%, respectively. Most adverse events were mild to moderate in intensity; there were no deaths, and serious adverse events and adverse events leading to study discontinuation were rare. These results indicate that isavuconazole is a sensitive substrate and moderate inhibitor of CYP3A4. |
|---|---|
| AbstractList | This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and isavuconazole's effects on CYP3A4-mediated metabolism in healthy adults. Coadministration of oral isavuconazole (100 mg once daily) with oral rifampin (600 mg once daily; CYP3A4 inducer) decreased isavuconazole area under the concentration-time curve (AUCτ) during a dosing interval by 90% and maximum concentration (Cmax) by 75%. Conversely, coadministration of isavuconazole (200 mg single dose) with oral ketoconazole (200 mg twice daily; CYP3A4 inhibitor) increased isavuconazole AUC from time 0 to infinity (AUC0-[infin]) and Cmax by 422% and 9%, respectively. Isavuconazole was coadministered (200 mg 3 times daily for 2 days, then 200 mg once daily) with single doses of oral midazolam (3 mg; CYP3A4 substrate) or ethinyl estradiol/norethindrone (35 µg/1 mg; CYP3A4 substrate). Following coadministration, AUC0-[infin] increased 103% for midazolam, 8% for ethinyl estradiol, and 16% for norethindrone; Cmax increased by 72%, 14%, and 6%, respectively. Most adverse events were mild to moderate in intensity; there were no deaths, and serious adverse events and adverse events leading to study discontinuation were rare. These results indicate that isavuconazole is a sensitive substrate and moderate inhibitor of CYP3A4. This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and isavuconazole's effects on CYP3A4-mediated metabolism in healthy adults. Coadministration of oral isavuconazole (100 mg once daily) with oral rifampin (600 mg once daily; CYP3A4 inducer) decreased isavuconazole area under the concentration-time curve (AUCτ ) during a dosing interval by 90% and maximum concentration (Cmax ) by 75%. Conversely, coadministration of isavuconazole (200 mg single dose) with oral ketoconazole (200 mg twice daily; CYP3A4 inhibitor) increased isavuconazole AUC from time 0 to infinity (AUC0-∞ ) and Cmax by 422% and 9%, respectively. Isavuconazole was coadministered (200 mg 3 times daily for 2 days, then 200 mg once daily) with single doses of oral midazolam (3 mg; CYP3A4 substrate) or ethinyl estradiol/norethindrone (35 μg/1 mg; CYP3A4 substrate). Following coadministration, AUC0-∞ increased 103% for midazolam, 8% for ethinyl estradiol, and 16% for norethindrone; Cmax increased by 72%, 14%, and 6%, respectively. Most adverse events were mild to moderate in intensity; there were no deaths, and serious adverse events and adverse events leading to study discontinuation were rare. These results indicate that isavuconazole is a sensitive substrate and moderate inhibitor of CYP3A4.This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and isavuconazole's effects on CYP3A4-mediated metabolism in healthy adults. Coadministration of oral isavuconazole (100 mg once daily) with oral rifampin (600 mg once daily; CYP3A4 inducer) decreased isavuconazole area under the concentration-time curve (AUCτ ) during a dosing interval by 90% and maximum concentration (Cmax ) by 75%. Conversely, coadministration of isavuconazole (200 mg single dose) with oral ketoconazole (200 mg twice daily; CYP3A4 inhibitor) increased isavuconazole AUC from time 0 to infinity (AUC0-∞ ) and Cmax by 422% and 9%, respectively. Isavuconazole was coadministered (200 mg 3 times daily for 2 days, then 200 mg once daily) with single doses of oral midazolam (3 mg; CYP3A4 substrate) or ethinyl estradiol/norethindrone (35 μg/1 mg; CYP3A4 substrate). Following coadministration, AUC0-∞ increased 103% for midazolam, 8% for ethinyl estradiol, and 16% for norethindrone; Cmax increased by 72%, 14%, and 6%, respectively. Most adverse events were mild to moderate in intensity; there were no deaths, and serious adverse events and adverse events leading to study discontinuation were rare. These results indicate that isavuconazole is a sensitive substrate and moderate inhibitor of CYP3A4. This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and isavuconazole's effects on CYP3A4‐mediated metabolism in healthy adults. Coadministration of oral isavuconazole (100 mg once daily) with oral rifampin (600 mg once daily; CYP3A4 inducer) decreased isavuconazole area under the concentration‐time curve (AUC τ ) during a dosing interval by 90% and maximum concentration (C max ) by 75%. Conversely, coadministration of isavuconazole (200 mg single dose) with oral ketoconazole (200 mg twice daily; CYP3A4 inhibitor) increased isavuconazole AUC from time 0 to infinity (AUC 0‐∞ ) and C max by 422% and 9%, respectively. Isavuconazole was coadministered (200 mg 3 times daily for 2 days, then 200 mg once daily) with single doses of oral midazolam (3 mg; CYP3A4 substrate) or ethinyl estradiol/norethindrone (35 μg/1 mg; CYP3A4 substrate). Following coadministration, AUC 0‐∞ increased 103% for midazolam, 8% for ethinyl estradiol, and 16% for norethindrone; C max increased by 72%, 14%, and 6%, respectively. Most adverse events were mild to moderate in intensity; there were no deaths, and serious adverse events and adverse events leading to study discontinuation were rare. These results indicate that isavuconazole is a sensitive substrate and moderate inhibitor of CYP3A4. This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and isavuconazole's effects on CYP3A4-mediated metabolism in healthy adults. Coadministration of oral isavuconazole (100 mg once daily) with oral rifampin (600 mg once daily; CYP3A4 inducer) decreased isavuconazole area under the concentration-time curve (AUC ) during a dosing interval by 90% and maximum concentration (C ) by 75%. Conversely, coadministration of isavuconazole (200 mg single dose) with oral ketoconazole (200 mg twice daily; CYP3A4 inhibitor) increased isavuconazole AUC from time 0 to infinity (AUC ) and C by 422% and 9%, respectively. Isavuconazole was coadministered (200 mg 3 times daily for 2 days, then 200 mg once daily) with single doses of oral midazolam (3 mg; CYP3A4 substrate) or ethinyl estradiol/norethindrone (35 μg/1 mg; CYP3A4 substrate). Following coadministration, AUC increased 103% for midazolam, 8% for ethinyl estradiol, and 16% for norethindrone; C increased by 72%, 14%, and 6%, respectively. Most adverse events were mild to moderate in intensity; there were no deaths, and serious adverse events and adverse events leading to study discontinuation were rare. These results indicate that isavuconazole is a sensitive substrate and moderate inhibitor of CYP3A4. This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and isavuconazole's effects on CYP3A4‐mediated metabolism in healthy adults. Coadministration of oral isavuconazole (100 mg once daily) with oral rifampin (600 mg once daily; CYP3A4 inducer) decreased isavuconazole area under the concentration‐time curve (AUCτ) during a dosing interval by 90% and maximum concentration (Cmax) by 75%. Conversely, coadministration of isavuconazole (200 mg single dose) with oral ketoconazole (200 mg twice daily; CYP3A4 inhibitor) increased isavuconazole AUC from time 0 to infinity (AUC0‐∞) and Cmax by 422% and 9%, respectively. Isavuconazole was coadministered (200 mg 3 times daily for 2 days, then 200 mg once daily) with single doses of oral midazolam (3 mg; CYP3A4 substrate) or ethinyl estradiol/norethindrone (35 μg/1 mg; CYP3A4 substrate). Following coadministration, AUC0‐∞ increased 103% for midazolam, 8% for ethinyl estradiol, and 16% for norethindrone; Cmax increased by 72%, 14%, and 6%, respectively. Most adverse events were mild to moderate in intensity; there were no deaths, and serious adverse events and adverse events leading to study discontinuation were rare. These results indicate that isavuconazole is a sensitive substrate and moderate inhibitor of CYP3A4. |
| Author | Lademacher, Christopher Lasseter, Kenneth Rammelsberg, Diane Dietz, Albert Hale, Christine Kowalski, Donna Townsend, Robert Akhtar, Shahzad Pearlman, Helene Yamazaki, Takao Desai, Amit Schmitt‐Hoffmann, Anne |
| AuthorAffiliation | 5 Randstad Pharma Deerfield IL USA 1 Astellas Pharma Global Development, Inc Northbrook IL USA 3 Covance Clinical Research Madison WI USA 4 Clinical Pharmacology of Miami, Inc Miami FL USA 6 Basilea Pharmaceutica International Ltd Basel Switzerland 2 Spaulding Clinical Research, LLC West Bend WI USA |
| AuthorAffiliation_xml | – name: 3 Covance Clinical Research Madison WI USA – name: 1 Astellas Pharma Global Development, Inc Northbrook IL USA – name: 4 Clinical Pharmacology of Miami, Inc Miami FL USA – name: 5 Randstad Pharma Deerfield IL USA – name: 2 Spaulding Clinical Research, LLC West Bend WI USA – name: 6 Basilea Pharmaceutica International Ltd Basel Switzerland |
| Author_xml | – sequence: 1 givenname: Robert surname: Townsend fullname: Townsend, Robert email: robert.townsend@astellas.com organization: Astellas Pharma Global Development, Inc – sequence: 2 givenname: Albert surname: Dietz fullname: Dietz, Albert organization: Spaulding Clinical Research, LLC – sequence: 3 givenname: Christine surname: Hale fullname: Hale, Christine organization: Covance Clinical Research – sequence: 4 givenname: Shahzad surname: Akhtar fullname: Akhtar, Shahzad organization: Astellas Pharma Global Development, Inc – sequence: 5 givenname: Donna surname: Kowalski fullname: Kowalski, Donna organization: Astellas Pharma Global Development, Inc – sequence: 6 givenname: Christopher surname: Lademacher fullname: Lademacher, Christopher organization: Astellas Pharma Global Development, Inc – sequence: 7 givenname: Kenneth surname: Lasseter fullname: Lasseter, Kenneth organization: Clinical Pharmacology of Miami, Inc – sequence: 8 givenname: Helene surname: Pearlman fullname: Pearlman, Helene organization: Astellas Pharma Global Development, Inc – sequence: 9 givenname: Diane surname: Rammelsberg fullname: Rammelsberg, Diane organization: Randstad Pharma – sequence: 10 givenname: Anne surname: Schmitt‐Hoffmann fullname: Schmitt‐Hoffmann, Anne organization: Basilea Pharmaceutica International Ltd – sequence: 11 givenname: Takao surname: Yamazaki fullname: Yamazaki, Takao organization: Astellas Pharma Global Development, Inc – sequence: 12 givenname: Amit surname: Desai fullname: Desai, Amit organization: Astellas Pharma Global Development, Inc |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27273461$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks9uEzEQxleoiJZSiSdAlrj0kKS217vevSBFaaARLUQIBJwsx_Y2Ll472N6gcOIReBvehyfBS5rwR-DLjD0_f_pGM_ezA-usyrKHCI4QhPhMrKQc4aq4kx1hVMIhLUl1sM_zd4fZSQg3MJ0SIoTIvewQU0xzUqKj7Nt8yX3LhfugrYpagOmam45H7SxwDZi8n-dj8v3L1yslNY9KgnPfXad7H8DMRuW56OHQ07PA151wln92RoG3Oi7BK93wdqXtADxX0e1qA3ClZZ_xdgC4lWAal9puDJiG6LnUzpy9cF71j9KnboG24EJxE5cbMJadieFBdrfhJqiT23icvXk6fT25GF6-fDabjC-HguRVMcSLnGLelEhRWVBectxwQmrJFwrRAqoFFTWRdZ5TgnOuEi6aRjaEKFoRTGB-nD3Z6q66RaukUDYZNGzldcv9hjmu2Z8Vq5fs2q1ZgesK5kUSOL0V8O5jp0JkrQ5CGcOtcl1gqMJlWVNS04Q-_gu9cZ23qb1EFXUBKaQ4UY9-d7S3sptpAkZbQHgXglcNEzr-nGgyqA1DkPV7w_q9YWlvflncf9hp_gMdbtFP2qjNfzk2mZ-f9_wPZgLXPA |
| CitedBy_id | crossref_primary_10_1111_bcp_15278 crossref_primary_10_1080_17425255_2017_1391213 crossref_primary_10_3390_microorganisms11092229 crossref_primary_10_1097_FTD_0000000000000952 crossref_primary_10_3390_jof7050378 crossref_primary_10_1128_AAC_02032_20 crossref_primary_10_1002_cpdd_376 crossref_primary_10_1007_s40262_018_0673_2 crossref_primary_10_1080_03007995_2018_1502659 crossref_primary_10_1111_myc_12731 crossref_primary_10_1002_phar_2348 crossref_primary_10_3390_jof8070674 crossref_primary_10_1111_myc_13300 crossref_primary_10_1007_s15010_017_1042_z crossref_primary_10_3238_PersInfek_2017_04_28_08 crossref_primary_10_1080_24745332_2022_2039500 crossref_primary_10_1186_s12885_024_12904_4 crossref_primary_10_1124_dmd_124_001809 crossref_primary_10_1007_s40262_021_01051_9 crossref_primary_10_1007_s00277_020_04107_1 crossref_primary_10_1007_s40265_016_0652_6 crossref_primary_10_1007_s00204_020_02936_7 crossref_primary_10_1093_jac_dkae240 crossref_primary_10_1128_AAC_01043_21 crossref_primary_10_1002_jcph_1622 crossref_primary_10_3389_fmicb_2024_1504826 crossref_primary_10_3390_pharmaceutics13111961 crossref_primary_10_1111_cts_13595 crossref_primary_10_1080_14656566_2024_2326507 crossref_primary_10_1016_j_idcr_2019_e00537 crossref_primary_10_1080_17425255_2021_1890715 crossref_primary_10_1093_jac_dkx027 crossref_primary_10_1016_j_ijantimicag_2017_09_002 crossref_primary_10_1093_jac_dkae439 crossref_primary_10_3390_pharmaceutics13122099 crossref_primary_10_1007_s12281_017_0287_4 crossref_primary_10_1016_j_ijantimicag_2020_106165 crossref_primary_10_3389_fmicb_2024_1468383 crossref_primary_10_1177_10781552211029046 crossref_primary_10_1080_17476348_2017_1325322 crossref_primary_10_1016_j_riam_2018_04_003 crossref_primary_10_1007_s11095_023_03507_y crossref_primary_10_1128_AAC_01728_19 crossref_primary_10_1016_j_cmi_2020_05_037 crossref_primary_10_1159_000513989 crossref_primary_10_1128_AAC_00401_20 crossref_primary_10_3389_fphar_2023_1168852 crossref_primary_10_1080_24745332_2023_2226009 crossref_primary_10_3389_fmicb_2025_1525991 crossref_primary_10_1002_cpdd_280 crossref_primary_10_1002_cpdd_1101 crossref_primary_10_1016_j_jpba_2020_113386 crossref_primary_10_2174_0113894501337502241015121015 crossref_primary_10_1016_j_mycmed_2018_02_002 crossref_primary_10_1007_s40261_023_01265_8 crossref_primary_10_1159_000530447 crossref_primary_10_1128_aac_01650_23 crossref_primary_10_3390_jcm11195756 crossref_primary_10_1111_tid_12751 crossref_primary_10_1007_s40268_018_0251_y crossref_primary_10_1002_jcph_1765 crossref_primary_10_1016_j_jaclp_2025_03_001 crossref_primary_10_1097_TP_0000000000004312 crossref_primary_10_1002_jcph_2212 crossref_primary_10_1097_FTD_0000000000000524 crossref_primary_10_3390_jof7020076 crossref_primary_10_1111_myc_12769 crossref_primary_10_1007_s00228_022_03378_z crossref_primary_10_1002_cpdd_284 crossref_primary_10_1007_s00063_025_01265_w crossref_primary_10_1177_0897190018790688 crossref_primary_10_1002_cpdd_283 crossref_primary_10_1016_j_livres_2019_08_001 crossref_primary_10_1093_mmy_myz012 crossref_primary_10_1124_dmd_122_000854 crossref_primary_10_1002_cpdd_282 crossref_primary_10_2147_IDR_S434622 crossref_primary_10_1002_cpdd_281 crossref_primary_10_1002_cpdd_1079 crossref_primary_10_1080_14656566_2022_2032645 crossref_primary_10_1038_s41598_023_31788_1 crossref_primary_10_1128_AAC_01643_18 crossref_primary_10_4155_tde_2023_0090 |
| Cites_doi | 10.1097/00000539-199603000-00015 10.1126/scitranslmed.3004404 10.2174/138920009788499012 10.12703/P6-81 10.1016/j.diagmicrobio.2012.06.012 10.1016/S0029-7844(01)01443-0 10.1111/j.1365-2125.2007.03084.x 10.1007/s002280050223 10.1128/AAC.04586-14 10.1185/03007995.2012.747952 10.1016/S0140-6736(15)01159-9 10.1016/S1473-3099(16)00071-2 10.1002/phar.1652 10.5414/CP202434 10.1002/cpdd.284 10.2165/00003088-200038020-00002 10.1093/cid/civ571 10.1111/bcp.12668 10.1002/cpdd.282 |
| ContentType | Journal Article |
| Copyright | 2016, The Authors. Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology 2016, The Authors. Clinical Pharmacology in Drug Development Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology. American College of Clinical Pharmacology |
| Copyright_xml | – notice: 2016, The Authors. Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology – notice: 2016, The Authors. Clinical Pharmacology in Drug Development Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology. – notice: American College of Clinical Pharmacology |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 5PM |
| DOI | 10.1002/cpdd.285 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| DocumentTitleAlternate | Townsend et al |
| EISSN | 2160-7648 |
| EndPage | 53 |
| ExternalDocumentID | PMC5298035 4303716451 27273461 10_1002_cpdd_285 CPDD285 |
| Genre | article Journal Article Clinical Trial, Phase I |
| GrantInformation_xml | – fundername: Astellas Pharma Global Development, Inc. – fundername: Basilea Pharmaceutica International Ltd. |
| GroupedDBID | -MK 05W 0R~ 1OC 24P 33P 3SF 52U 52V 53G 8-1 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AAXRX AAYCA AAZKR ABCUV ABDBF ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACRPL ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUYR AFBPY AFFPM AFGKR AFPWT AFWVQ AHBTC AIACR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BNHUX BOGZA BRXPI C45 DCZOG DPXWK DRFUL DRMAN DRSTM EBS EJD FUBAC G-S GODZA H13 HGLYW KBYEO LATKE LEEKS LH4 LITHE LOXES LSO LUTES LW6 LYRES MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ O66 O9- OVD P2W PQQKQ R.K ROL SUPJJ TEORI TUS WBKPD WIH WIJ WIK WOHZO WOIKV WPGGZ WXSBR WYJ ZZTAW AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM AAMMB AEFGJ AGXDD AIDQK AIDYY K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c4385-2b372af61e7d57a6a2fa449dabe1750eb7c94d9337423ae2b3cffdf44e7842403 |
| IEDL.DBID | 24P |
| ISSN | 2160-763X 2160-7648 |
| IngestDate | Thu Aug 21 14:08:30 EDT 2025 Fri Jul 11 04:27:48 EDT 2025 Mon Jul 14 08:53:19 EDT 2025 Thu Apr 03 07:08:25 EDT 2025 Thu Apr 24 22:58:49 EDT 2025 Tue Jul 01 00:19:10 EDT 2025 Wed Jan 22 16:32:28 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | ethinyl estradiol/norethindrone ketoconazole isavuconazole midazolam rifampin |
| Language | English |
| License | Attribution-NonCommercial http://creativecommons.org/licenses/by-nc/4.0 2016, The Authors. Clinical Pharmacology in Drug Development Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4385-2b372af61e7d57a6a2fa449dabe1750eb7c94d9337423ae2b3cffdf44e7842403 |
| Notes | Fellow of the American College of Clinical Pharmacology ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpdd.285 |
| PMID | 27273461 |
| PQID | 1859507072 |
| PQPubID | 2034576 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5298035 proquest_miscellaneous_1826697497 proquest_journals_1859507072 pubmed_primary_27273461 crossref_citationtrail_10_1002_cpdd_285 crossref_primary_10_1002_cpdd_285 wiley_primary_10_1002_cpdd_285_CPDD285 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January/February 2017 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – month: 01 year: 2017 text: January/February 2017 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Oxford – name: Hoboken |
| PublicationTitle | Clinical pharmacology in drug development |
| PublicationTitleAlternate | Clin Pharmacol Drug Dev |
| PublicationYear | 2017 |
| Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
| References | 2015; 35 2013; 29 2017; 6 2015; 59 1997; 51 2009; 10 2000; 38 2015; 61 2016; 387 1996; 82 2016 2008; 65 2015; 80 2012; 4 2016; 16 2014; 6 2012; 73 2001; 98 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_20_1 25561337 - Antimicrob Agents Chemother. 2015 Mar;59(3):1671-9 26179012 - Clin Infect Dis. 2015 Nov 15;61(10):1558-65 25343038 - F1000Prime Rep. 2014 Sep 04;6:81 22789847 - Diagn Microbiol Infect Dis. 2012 Aug;73(4):293-300 8623953 - Anesth Analg. 1996 Mar;82(3):511-6 11506836 - Obstet Gynecol. 2001 Aug;98(2):218-23 23253612 - Sci Transl Med. 2012 Dec 19;4(165):165rv13 19519346 - Curr Drug Metab. 2009 May;10(4):395-409 18294327 - Br J Clin Pharmacol. 2008 Apr;65(4):531-9 23136913 - Curr Med Res Opin. 2013 Jan;29(1):1-12 27345284 - Int J Clin Pharmacol Ther. 2016 Aug;54(8):572-80 25923589 - Br J Clin Pharmacol. 2015 Sep;80(3):342-50 10709776 - Clin Pharmacokinet. 2000 Feb;38(2):111-80 27273248 - Clin Pharmacol Drug Dev. 2017 Jan;6(1):93-101 26684607 - Lancet. 2016 Feb 20;387(10020):760-9 9049584 - Eur J Clin Pharmacol. 1997;51(5):415-9 26969258 - Lancet Infect Dis. 2016 Jul;16(7):828-37 27273343 - Clin Pharmacol Drug Dev. 2017 Jan;6(1):76-85 26598096 - Pharmacotherapy. 2015 Nov;35(11):1037-51 |
| References_xml | – volume: 387 start-page: 760 year: 2016 end-page: 769 article-title: Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by and other filamentous fungi (SECURE): a phase 3, randomised‐controlled, non‐inferiority trial publication-title: Lancet – year: 2016 article-title: Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH publication-title: Int J Clin Pharmacol Ther – volume: 80 start-page: 342 year: 2015 end-page: 350 article-title: Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450‐3A in drug‐drug interaction studies publication-title: Br J Clin Pharmacol – volume: 6 start-page: 81 year: 2014 article-title: Epidemiology of invasive fungal diseases on the basis of autopsy reports publication-title: F1000 Prime Rep – volume: 61 start-page: 1558 year: 2015 end-page: 1565 article-title: Isavuconazole: a new broad‐spectrum triazole antifungal agent publication-title: Clin Infect Dis – volume: 10 start-page: 395 year: 2009 end-page: 409 article-title: Drug‐drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care publication-title: Curr Drug Metab – volume: 98 start-page: 218 year: 2001 end-page: 223 article-title: Evaluation of interaction between fluconazole and an oral contraceptive in healthy women publication-title: Obstet Gynecol – volume: 38 start-page: 111 year: 2000 end-page: 180 article-title: Effects of the antifungal agents on oxidative drug metabolism: clinical relevance publication-title: Clin Pharmacokinet – volume: 35 start-page: 1037 year: 2015 end-page: 1051 article-title: Isavuconazole: pharmacology, pharmacodynamics, and current clinical experience with a new triazole antifungal agent publication-title: Pharmacotherapy – volume: 82 start-page: 511 year: 1996 end-page: 516 article-title: The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam publication-title: Anesth Analg – volume: 6 start-page: 93 year: 2017 end-page: 101 article-title: Pharmacokinetic interaction between isavuconazole and a fixed‐dose combination of lopinavir 400 mg/ritonavir 100 mg in healthy subjects publication-title: Clin Pharm Drug Dev – volume: 73 start-page: 293 year: 2012 end-page: 300 article-title: The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: update 2012 publication-title: Diagn Microbiol Infect Dis – volume: 4 start-page: 165rv113 year: 2012 article-title: Hidden killers: human fungal infections publication-title: Sci Transl Med – volume: 16 start-page: 828 year: 2016 end-page: 837 article-title: Isavuconazole treatment for mucormycosis: a single‐arm open‐label trial and case‐control analysis publication-title: Lancet Infect Dis – volume: 59 start-page: 1671 year: 2015 end-page: 1679 article-title: A phase 2, randomized, double‐blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis publication-title: Antimicrob Agents Chemother – volume: 29 start-page: 1 year: 2013 end-page: 12 article-title: Update on rifampin, rifabutin, and rifapentine drug interactions publication-title: Curr Med Res Opin – volume: 51 start-page: 415 year: 1997 end-page: 419 article-title: Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam publication-title: Eur J Clin Pharmacol – volume: 6 start-page: 44 year: 2017 end-page: 53 article-title: Pharmacokinetic assessment of drug‐drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults publication-title: Clin Pharmacol Drug Dev – volume: 65 start-page: 531 year: 2008 end-page: 539 article-title: Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co‐administered in healthy female subjects publication-title: Br J Clin Pharmacol – ident: e_1_2_7_19_1 doi: 10.1097/00000539-199603000-00015 – ident: e_1_2_7_3_1 doi: 10.1126/scitranslmed.3004404 – ident: e_1_2_7_10_1 doi: 10.2174/138920009788499012 – ident: e_1_2_7_4_1 doi: 10.12703/P6-81 – ident: e_1_2_7_2_1 doi: 10.1016/j.diagmicrobio.2012.06.012 – ident: e_1_2_7_17_1 doi: 10.1016/S0029-7844(01)01443-0 – ident: e_1_2_7_16_1 doi: 10.1111/j.1365-2125.2007.03084.x – ident: e_1_2_7_18_1 doi: 10.1007/s002280050223 – ident: e_1_2_7_13_1 doi: 10.1128/AAC.04586-14 – ident: e_1_2_7_14_1 doi: 10.1185/03007995.2012.747952 – ident: e_1_2_7_5_1 doi: 10.1016/S0140-6736(15)01159-9 – ident: e_1_2_7_6_1 doi: 10.1016/S1473-3099(16)00071-2 – ident: e_1_2_7_7_1 doi: 10.1002/phar.1652 – ident: e_1_2_7_9_1 doi: 10.5414/CP202434 – ident: e_1_2_7_20_1 doi: 10.1002/cpdd.284 – ident: e_1_2_7_11_1 doi: 10.2165/00003088-200038020-00002 – ident: e_1_2_7_8_1 doi: 10.1093/cid/civ571 – ident: e_1_2_7_12_1 doi: 10.1111/bcp.12668 – ident: e_1_2_7_15_1 doi: 10.1002/cpdd.282 – reference: 18294327 - Br J Clin Pharmacol. 2008 Apr;65(4):531-9 – reference: 26684607 - Lancet. 2016 Feb 20;387(10020):760-9 – reference: 25923589 - Br J Clin Pharmacol. 2015 Sep;80(3):342-50 – reference: 27345284 - Int J Clin Pharmacol Ther. 2016 Aug;54(8):572-80 – reference: 10709776 - Clin Pharmacokinet. 2000 Feb;38(2):111-80 – reference: 27273248 - Clin Pharmacol Drug Dev. 2017 Jan;6(1):93-101 – reference: 26598096 - Pharmacotherapy. 2015 Nov;35(11):1037-51 – reference: 19519346 - Curr Drug Metab. 2009 May;10(4):395-409 – reference: 27273343 - Clin Pharmacol Drug Dev. 2017 Jan;6(1):76-85 – reference: 11506836 - Obstet Gynecol. 2001 Aug;98(2):218-23 – reference: 25561337 - Antimicrob Agents Chemother. 2015 Mar;59(3):1671-9 – reference: 22789847 - Diagn Microbiol Infect Dis. 2012 Aug;73(4):293-300 – reference: 8623953 - Anesth Analg. 1996 Mar;82(3):511-6 – reference: 9049584 - Eur J Clin Pharmacol. 1997;51(5):415-9 – reference: 25343038 - F1000Prime Rep. 2014 Sep 04;6:81 – reference: 23253612 - Sci Transl Med. 2012 Dec 19;4(165):165rv13 – reference: 26179012 - Clin Infect Dis. 2015 Nov 15;61(10):1558-65 – reference: 23136913 - Curr Med Res Opin. 2013 Jan;29(1):1-12 – reference: 26969258 - Lancet Infect Dis. 2016 Jul;16(7):828-37 |
| SSID | ssj0000601114 |
| Score | 2.3461943 |
| Snippet | This report describes the phase 1 trials that evaluated the metabolism of the novel triazole antifungal isavuconazole by cytochrome P450 3A4 (CYP3A4) and... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 44 |
| SubjectTerms | Adult Antifungal Agents - administration & dosage Antifungal Agents - pharmacokinetics Area Under Curve Cross-Over Studies Cytochrome P-450 CYP3A - metabolism Drug Interactions ethinyl estradiol/norethindrone Female Healthy Volunteers Humans isavuconazole ketoconazole Ketoconazole - administration & dosage Male Metabolism midazolam Midazolam - administration & dosage Middle Aged Nitriles - administration & dosage Nitriles - pharmacokinetics Norethindrone - administration & dosage Original Manuscript Prescription drugs Pyridines - administration & dosage Pyridines - pharmacokinetics rifampin Rifampin - administration & dosage Side effects Triazoles - administration & dosage Triazoles - pharmacokinetics |
| Title | Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpdd.285 https://www.ncbi.nlm.nih.gov/pubmed/27273461 https://www.proquest.com/docview/1859507072 https://www.proquest.com/docview/1826697497 https://pubmed.ncbi.nlm.nih.gov/PMC5298035 |
| Volume | 6 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjZ1bb9MwFMct2F54QYxr2ZiMhMpLQhPHuT12vWiAOkVoE-UpsmOHRXRJ1bRI5YmPwLfh-_BJOCe3Ug0kHqIk9WmTyj7x3yc-PxPyintekrLQMhPJYYAC8s0Unm2bLFBBattSMo1xyNmFd37F383deTOrEnNhaj5EF3BDz6ie1-jgQpaDHTQ0WSr1hgXuXXKImbU4nY_xqIuvIGfErtDezPYsE9xo3rJnLTZov7zfG92SmLdnSv6pYKsuaPqA3G-0Ix3WlX1E7uj8IelHNXx6a9DLXS5VadA-jXZY6u0j8rM9_QJ_HUzopAN90yKlo0-RM-S_vv-YVYt3aEXHq81nOMcdrQKHdQ5EidZvS_F1A0Np8a1YaPoxW1_TD1kqbpZZbtD3el20ZQadZQqPxI1BRa4oTrDPtws6wRiLyorF4AIzKeFDtSpyTbOc1qlRWzpENkj5mFxNJ5ejc7NZtsFMuBO4JpOOz0Tq2dpXri88wVLBeaiE1KBVLC39JOQqdBx8SSw0mCdpqlLOtR9wxAM-IQc5XPAZobZyBCLhlAKlY4VB6EvYcAyXykAy1SOv2-qLk4ZpjktrLOKaxsxirOgYKrpHXnaWy5rj8Rebk7YFxI0nl7GNADhkIjH4ia4YfBBfrIhcFxu0AZkDA7PQ75GndYPpLsJQIHLP7hF_ryl1Bsj33i_Js-uK8-2yMLAcuK1-1ej-ed_xKBqPYf_8fw2PyT2G6qSKJJ2Qg_Vqo1-AtlrL08qJTsnh8Gx8Nv0N5mYoqQ |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NjtMwELaW5QAXxD-FBYwE5dLQxHHzc-BQtV21dFtFqCvKKTixw0Z0k6ppQeHEI_AePADvw5MwkzQp1YLEZQ9RfjxKrMxM_M3E85mQ59yywoi5uhYGHAIUgG-asAxDY450IsMIAqYwDzmZWsNT_mbemR-QH1UtTMkPUSfc0DOK7zU6OCak2zvW0HAp5SvmVDMqxyr_AvFa9nrUB-W-YOx4MOsNte2SAlrITaejscC0mYgsQ9myYwtLsEhw7koRKBhHdRXYocslBPn4A1MoEA-jSEacK9vhSF0H971CrnKL2bhcAuNendBBYhOj4BJnhqVr4LfziuxWZ-2qs_vD3wVMe3Fq5p-QuRjzjm-SG1uwSruldd0iByq5TZpeyXadt-hsV7yVtWiTejse7PwO-VmdfoJ3DSJ0UDOL0zSivfee2eW_vn2fFKuFKEn7q81HOMcdLTKVZdFFhtKjTHzeQOwuvqYLRd_F6zP6No7E-TJOWnSs1mnV1qKTWOKROG9RkUiKM_qTfEEHmNSRcbpoT7F0Ey7KVZooGie0rMXKaRfJSLK75PRSlHqPHCbwwAeEGtIUyEEnJUAr3XVcO4ANg8YocAImG-RlpT4_3JKo41oeC7-kf2Y-KtoHRTfIs1pyWRKH_EXmqLIAf_vpyHwDGeeQhInBLepmcHr8kyMSlW5QBnAVRIKu3SD3S4OpH8IQkXLLaBB7z5RqASQU329J4rOCWLzDXEc3oVvNwuj-2W-_5_X7sH_4v4JPybXhbHLin4ym40fkOkNoVKSxjsjherVRjwHYrYMnhUNR8uGyPfg3i-1kvQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NjtMwELaWRUJcEP90WcBIUC4NTVw3PwcOVX-0pbSK0K4op6wT22y03aRqWlA58Qg8By_A-_AkzCRNSrUgcdlDlKQeJVZnJv5m7PlMyAtu25FmnmlEIYcABeCbIWzLMpgrXW1ZYcgU5iHHE_vohL-dtqd75EdZC1PwQ1QJN_SM_HuNDj6XurklDY3mUr5mbrmgcqTWXyBcy94Me6Dbl4wN-sfdI2Ozo4AR8ZbbNljYcpjQtqUc2XaELZgWnHtShAqGUVOFTuRxCTE-zl8KBeKR1lJzrhyXI3MdPPcauY5zi7h8jHG_yucgr4mVU4kzyzYNcNtpyXVrsmbZ2d3R7xKkvbwy80_EnA95g9vk1gar0k5hXHfInkrukrpfkF2vG_R4W7uVNWid-lsa7PU98rO8PYe_GkRovyIWp6mm3Y9-q8N_ffs-zjcLUZL2FqtPcI8nmicqi5qLDKWHmfi8gtBdfE1nin6Il2f0fazFxTxOGnSklmnZ1qDjWOKVuGhQkUiKC_qT9Yz2Macj43TWnGDlJvwoF2miaJzQohRrTTvIRZLdJydXotQHZD-BFz4i1JItgRR0UgKyMj3Xc0I4MGbUoRsyWSOvSvUF0YZDHbfymAUF-zMLUNEBKLpGnleS84I35C8yh6UFBJsvRxZYSDiHHEwMHlE1g8_jRI5IVLpCGYBVEAh6To08LAymeglDQMptq0acHVOqBJBPfLclic9yXvE281yzBd2q50b3z34HXb_Xg_PB_wo-Izf83iB4N5yMHpObDIFRnsQ6JPvLxUo9AVi3DJ_m_kTJ6VU78G8Q8mPv |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetic+Evaluation+of+CYP3A4-Mediated+Drug-Drug+Interactions+of+Isavuconazole+With+Rifampin%2C+Ketoconazole%2C+Midazolam%2C+and+Ethinyl+Estradiol%2FNorethindrone+in+Healthy+Adults&rft.jtitle=Clinical+pharmacology+in+drug+development&rft.au=Townsend%2C+Robert&rft.au=Dietz%2C+Albert&rft.au=Hale%2C+Christine&rft.au=Akhtar%2C+Shahzad&rft.date=2017-01-01&rft.eissn=2160-7648&rft.volume=6&rft.issue=1&rft.spage=44&rft_id=info:doi/10.1002%2Fcpdd.285&rft_id=info%3Apmid%2F27273461&rft.externalDocID=27273461 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2160-763X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2160-763X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2160-763X&client=summon |